Advertisement

Topics

FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C

16:08 EDT 3 Aug 2017 | Drugs.com

August 3, 2017 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including...

Original Article: FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C"

Quick Search
Advertisement
 

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...